JAKi an option for Still’s Dz, especially refractory AOSD? Metanlysis of 9 studies (35 pts), Rx w/ either Tofa (17), Bari (14), Ruxo (4), Upa 1. Half had complete remission, 1/3 partial remission, 1/5 loss effect. Ruxolitinib 100% effective in AOSD w/ MAS https://t.co/3TKFNsj4v9 https://t.co/3yAXlcJ2sX